Singapore, July 15 -- US-based GEM Global Yield LLC SCS has executed a Share Purchase Agreement (SPA) with the existing shareholders of Taiwan-listed Senhwa Biosciences Inc., under which GEM has committed up to NT$500 million (approximately $15.5 million) to purchase shares in the company over the next 3-5 years.

Taiwan's biotechnology industry continues to attract increasing international attention through innovative oncology research, expanding global clinical collaborations and the adoption of artificial intelligence to accelerate drug discovery and clinical development.

Under the framework of the SPA, the equity commitment from GEM provides additional financial flexibility and is expected to support continued investment in Senhwa's ...